SAGE Therapeutics (SAGE) said Thursday it is cutting its workforce by 165 employees as part of a business reorganization, which it said it expects to be completed by the end of the year.
The biopharmaceutical company said the cuts equate to approximately 33% of its total workforce and approximately 55% of its research and design team.
SAGE also said it expects a non-recurring charge of approximately $26 million to $28 million related to the reorganization, most of which it said it will incur in Q4.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。